{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28for+Dupilumab%29", "query": { "intervention": "Placebo (for Dupilumab)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 63, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28for+Dupilumab%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-30T22:47:31.726Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04345367", "title": "Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Abrocitinib 200 mg", "type": "DRUG" }, { "name": "Dupilumab 300 mg", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 727, "start_date": "2020-06-11", "completion_date": "2021-07-13", "has_results": true, "last_update_posted_date": "2022-07-08", "last_synced_at": "2026-09-30T22:47:31.726Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04345367" }, { "nct_id": "NCT04183335", "title": "Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neurodermatitis" ], "interventions": [ { "name": "Dupilumab SAR231893", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moisturizers", "type": "DRUG" }, { "name": "Low to medium potent topical corticosteroids", "type": "DRUG" }, { "name": "Topical calcineurin inhibitors", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 151, "start_date": "2019-12-12", "completion_date": "2022-02-03", "has_results": true, "last_update_posted_date": "2025-09-17", "last_synced_at": "2026-09-30T22:47:31.726Z", "location_count": 21, "location_summary": "Gilbert, Arizona • Fort Smith, Arkansas • Sacramento, California + 18 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04183335" }, { "nct_id": "NCT04362501", "title": "Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Sinusitis" ], "interventions": [ { "name": "dupilumab", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 33, "start_date": "2020-10-15", "completion_date": "2025-09-30", "has_results": false, "last_update_posted_date": "2025-11-03", "last_synced_at": "2026-09-30T22:47:31.726Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04362501" }, { "nct_id": "NCT04998604", "title": "EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Rhinosinusitis With Nasal Polyps", "Asthma" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Omalizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 360, "start_date": "2021-09-27", "completion_date": "2024-12-27", "has_results": true, "last_update_posted_date": "2025-10-23", "last_synced_at": "2026-09-30T22:47:31.726Z", "location_count": 16, "location_summary": "Los Angeles, California • Tampa, Florida • Chicago, Illinois + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04998604" }, { "nct_id": "NCT02260986", "title": "Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo (for Dupilumab)", "type": "DRUG" }, { "name": "Topical Corticosteroid (TCS)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 740, "start_date": "2014-09", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2017-10-17", "last_synced_at": "2026-09-30T22:47:31.726Z", "location_count": 50, "location_summary": "Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Encinitas", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02260986" }, { "nct_id": "NCT07783425", "title": "A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Tilrekimig", "type": "DRUG" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo for Tilrekimig", "type": "OTHER" }, { "name": "Placebo for Dupilumab", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1375, "start_date": "2026-08-19", "completion_date": "2029-06-05", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-30T22:47:31.726Z", "location_count": 1, "location_summary": "Tulsa, Oklahoma", "locations": [ { "city": "Tulsa", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT07783425" }, { "nct_id": "NCT02277743", "title": "Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatitis, Atopic" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo (for Dupilumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 671, "start_date": "2014-10", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2017-11-21", "last_synced_at": "2026-09-30T22:47:31.726Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Clovis", "state": "California" }, { "city": "Lomita", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02277743" }, { "nct_id": "NCT02573233", "title": "Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Dupilumab SAR231893/REGN668", "type": "DRUG" }, { "name": "fluticasone propionate and salmeterol", "type": "DRUG" }, { "name": "budesonide and formoterol", "type": "DRUG" }, { "name": "mometasone furoate and formoterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 42, "start_date": "2016-01-27", "completion_date": "2018-01-03", "has_results": true, "last_update_posted_date": "2022-04-04", "last_synced_at": "2026-09-30T22:47:31.726Z", "location_count": 6, "location_summary": "Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02573233" }, { "nct_id": "NCT03346434", "title": "Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Dermatitis, Atopic" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "5 Years", "sex": "ALL", "summary": "6 Months to 5 Years" }, "enrollment_count": 202, "start_date": "2017-11-30", "completion_date": "2021-07-08", "has_results": true, "last_update_posted_date": "2022-07-28", "last_synced_at": "2026-09-30T22:47:31.726Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03346434" }, { "nct_id": "NCT02912468", "title": "A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)" ], "interventions": [ { "name": "Dupilumab SAR231893 (REGN668)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Mometasone furoate 50 micrograms", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 276, "start_date": "2016-12-05", "completion_date": "2018-07-05", "has_results": true, "last_update_posted_date": "2019-07-25", "last_synced_at": "2026-09-30T22:47:31.726Z", "location_count": 18, "location_summary": "Long Beach, California • Orange, California • San Diego, California + 15 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stockton", "state": "California" }, { "city": "Centennial", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02912468" } ] }